Atara Biotherapeutics (ATRA) Total Non-Current Liabilities (2013 - 2026)

Atara Biotherapeutics (ATRA) has reported Total Non-Current Liabilities for 14 consecutive years, with $16.5 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Non-Current Liabilities fell 47.09% year-over-year to $16.5 million; the trailing twelve-month figure through Jun 2026 stood at $16.5 million (down 47.09% YoY), and the FY2025 full-year result was $16.3 million, down 90.25% from the prior year.
• Total Non-Current Liabilities rose to $16.5 million in Q2 2026 per ATRA's latest filing, from $15.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $259.2 million in Q1 2024 and bottomed at $15.8 million in Q1 2026.
• Historically, Total Non-Current Liabilities has averaged $153.2 million across 5 years, with a median of $174.3 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 40.11% in 2022, then plunged 90.25% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $244.2 million in 2022, then slipped by 5.96% to $229.7 million in 2023, then declined by 27.12% to $167.4 million in 2024, then slumped by 90.25% to $16.3 million in 2025, then climbed by 1.03% to $16.5 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $16.5 million, $15.8 million, and $16.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.